AL 8697

AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC50 of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC50=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity.

Product information

CAS Number: 1057394-06-5

Molecular Weight: 402.41

Formula: C21H21F3N4O

Chemical Name: 3-{3-tert-butyl-6, 8-difluoro-[1, 2, 4]triazolo[4, 3-a]pyridin-7-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide

Smiles: CC1C(=CC(=CC=1F)C(=O)NC1CC1)C1C(F)=CN2C(=NN=C2C=1F)C(C)(C)C

InChiKey: ZVBTZTQYHOXIBC-UHFFFAOYSA-N

InChi: InChI=1S/C21H21F3N4O/c1-10-13(7-11(8-14(10)22)19(29)25-12-5-6-12)16-15(23)9-28-18(17(16)24)26-27-20(28)21(2,3)4/h7-9,12H,5-6H2,1-4H3,(H,25,29)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

AL 8697 (1-30 mg/kg; p.o.; once daily for 10 days) dose-dependently decreases the oedema in right and left paws.

References:

1. Balague C, et al. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study. Br J Pharmacol. 2012 Jun;166(4):1320-32.

Products are for research use only. Not for human use.